Karen Sinclair talks synthetic biology on the From Idea to Intellectual Property podcast
Karen Sinclair joins host Lisa Leong on the From Idea to Intellectual Property podcast series to discuss the emerging trends and key issues in the area of synthetic biology.
Reversal of fortune – Full Court decides that an artificial intelligence is not an “inventor”
Anthony Selleck reviews the decision in Commissioner of Patents v Thaler  FCAFC 62 which reverses an earlier ruling that artificial intelligence can be an “inventor” for the purposes of the Australian Patents Act 1990.
Spotlight Series: Regenerative Medicine – Part 2
Welcome to the second article of our Spotlight Series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Changes to how influencers can promote therapeutic goods in Australia
The Therapeutic Goods Administration has set out new guidelines that govern how influencers can promote products on social media in return for payment or free products or services from brands.
Federal Budget 2022: What’s in it to accelerate Australia’s innovation agenda?
We discuss the key measures in Australia’s 2022-23 federal budget that could help drive innovation, research commercialisation and business growth.
From idea to inception and beyond: Important learnings from female biotech founders
Female biotech founders took centre-stage at AusBiotech 2021 with the leaders of some of Australia’s most innovative start-ups coming together to discuss their experiences in the commercial scientific world.
Saving grace: Options if you disclose your invention without a patent application
Publicly disclosing new technology before a patent application has been filed can jeopardise patent coverage – but there are options available to you in the event of disclosure.
Virus filtration patent gets clean bill of health
In a recent decision of the Australian Patent Office, a patent application directed to a membrane for filtering biological products was upheld following opposition.
Extending the 12-month grace period for filing patent applications – what you need to know
Can the 12-month grace period for filing your patent application be extended? Yes, it can – but subject to the facts.
Why are embryonic stem cells not able to be patented in Australia?
Despite not being specifically excluded under s18 of the Australian Patents Act, technology utilising embryonic stem cells is not able to be patented in Australia. Why is this so?
Spotlight Series: Regenerative Medicine – Part 1
The first in a five-part series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Draft roadmap for Australian regenerative medicine released for comment
AusBiotech has released a draft strategic roadmap for a new regenerative medicine Catalyst.
Guidance on patenting diagnostics in Australia: Ariosa Diagnostics v Sequenom
Federal Court confirms that a non-invasive diagnostic test for prenatal conditions is patentable subject matter in Australia.
Australian government rediscovers R&D value amid COVID-19 crisis
Prior to COVID-19, Australia enjoyed an enviable economic record; outperforming much of the world and avoiding recession for 29 years.
Ono: Broader is not always better
Why is patent term extension is so important to companies developing and commercialising new pharmaceutical substances?
CRISPR-Cas9 Update: Collision of Trends in IP and Life Sciences
CRISPR-Cas9 genome editing may not just be the greatest scientific breakthrough of this century, but also provides many lessons on patenting life science technologies.